Note from the Communications Committee: We are looking for additional support in improving communication at Visible Alpha. This newsletter is a great step in the right direction, but there is more we can do with your help! Email [email protected] to learn how to get involved.
Teva Pharmaceutical Industries is down ~60% year-to-date amid competitive concerns surrounding its portfolio of drugs. Competitive concerns have largely been focused on two areas: the company’s Generic Medicines segment and the company’s Multiple Sclerosis drug, Copaxone. A closer look at the size of the revisions and investor growth expectations provides a justification for the poor stock performance for the year.
Last week, Bed Bath & Beyond reported 1Q17 results that were well-below expectations. The results were highlighted by -2.0% comparable store sales growth, which compared to the company’s full-year guidance of “relatively flat to slightly positive” comparable store sales growth. Reported EPS of $0.53 was also well-below consensus of $0.66. Read more…
With $1.9B in revenue last year, the Diabetes Group at Medtronic represented just 6% of sales. However, management is aiming to grow the segment significantly over the next several years.
LifePoint Health acquired eight healthcare facilities between 2015 and 2016 with a goal of bringing their EBITDA margins from single digits to double digits. Over one year later, investors are now looking for LifePoint Health to demonstrate overall company EBITDA margin expansion driven by operating efficiencies at those acquired hospitals.
Gilead reported 1Q17 earnings last week and missed earnings expectations. The miss was largely driven by its Hepatitis C (HCV) franchise, which was down 40% YoY.
Prior to Johnson & Johnson’s 1Q results on April 18, investors were concerned about the outlook for the Pharmaceutical segment. Pharmaceutical (Pharma) is the largest of the three segments, and represents 47% of sales. Investors have worried that growth within the Pharma segment would slow from its historical rate of double digit organic growth to a low single digit rate. A big factor for the decline was an expected slowdown in Remicade, as the drug faced competition from Pfizer’s Inflectra biosimilar, announced late last year.
